Takeda TOKYO4502NYSETAK today announced financial results for the third quarter of fiscal year 2023 period ended December 31 2023. With yeartodate strong momentum in its Growth Launch Products 12.7 at CER offsetting the significant revenue impact of generic entrants Takeda remains on track towards its fullyear Management Guidance.
Two New U.S. FDA Approvals in FY2023 Q3: FRUZAQLA for Adults With Previously Treated Metastatic Colorectal Cancer and ADZYNMA for Ultra-Rare Blood Clotting Disorder cTTPStrong Commercial Execution Maximizing Value of Existing Portfolio:ENTYVIO® Pen Launched in U.S. for Ulcerative Colitis; U.S. FDA Approval Decision.